This Clinical Studies/Trials Project is based on accomplishment over the past several years and continues to support two major initiatives (1) intensification of chemotherapy by regional Infusion"""""""" of the lung for patients with Soft Tissue Sarcoma metastatic to the lung. (2) Preclinical and clinical immunologic studies of high risk STS patients. In section 1a, phase I and phase II trials are ongoing and planned. Tissue obtained from patients in these studies will be sent to investigators in project 1b, 2, and 3 for analysis of tumor antigens, cell cycle regulators and mechanisms of drug resistance. In section 1b, preclinical studies are planned to define novel approaches for the development of tumor vaccines in order to delay or prevent progression of disease. Little is known about potential target on STS, except gangliosides and SYT_SSX fusion proteins, both under study in this Program Project. Therefore, we plan to identify antigens expressed by screening DNA libraries derived from autologous tumors, investigate peptide and DNA immunization against SYT_SSX fusion proteins, and evaluate immunizations against combinations of gangliosides in high risk patients. ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA047179-11
Application #
6424525
Study Section
Project Start
2001-03-01
Project End
2002-02-28
Budget Start
Budget End
Support Year
11
Fiscal Year
2001
Total Cost
$230,631
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Xie, Yuanyuan; Cao, Zhen; Wong, Elissa Wp et al. (2018) COP1/DET1/ETS axis regulates ERK transcriptome and sensitivity to MAPK inhibitors. J Clin Invest 128:1442-1457
Weinreb, Ilan; Bishop, Justin A; Chiosea, Simion I et al. (2018) Recurrent RET Gene Rearrangements in Intraductal Carcinomas of Salivary Gland. Am J Surg Pathol 42:442-452
Kao, Yu-Chien; Sung, Yun-Shao; Zhang, Lei et al. (2017) Expanding the molecular signature of ossifying fibromyxoid tumors with two novel gene fusions: CREBBP-BCORL1 and KDM2A-WWTR1. Genes Chromosomes Cancer 56:42-50
Seifert, Adrian M; Zeng, Shan; Zhang, Jennifer Q et al. (2017) PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors. Clin Cancer Res 23:454-465
Argani, Pedram; Zhang, Lei; Reuter, Victor E et al. (2017) RBM10-TFE3 Renal Cell Carcinoma: A Potential Diagnostic Pitfall Due to Cryptic Intrachromosomal Xp11.2 Inversion Resulting in False-negative TFE3 FISH. Am J Surg Pathol 41:655-662
Argani, Pedram; Zhong, Minghao; Reuter, Victor E et al. (2016) TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers. Am J Surg Pathol 40:723-37
Tan, Marcus C B; Brennan, Murray F; Kuk, Deborah et al. (2016) Histology-based Classification Predicts Pattern of Recurrence and Improves Risk Stratification in Primary Retroperitoneal Sarcoma. Ann Surg 263:593-600
Specht, Katja; Zhang, Lei; Sung, Yun-Shao et al. (2016) Novel BCOR-MAML3 and ZC3H7B-BCOR Gene Fusions in Undifferentiated Small Blue Round Cell Sarcomas. Am J Surg Pathol 40:433-42
Huang, Shih-Chiang; Ghossein, Ronald A; Bishop, Justin A et al. (2016) Novel PAX3-NCOA1 Fusions in Biphenotypic Sinonasal Sarcoma With Focal Rhabdomyoblastic Differentiation. Am J Surg Pathol 40:51-9
Dickson, Mark A; Schwartz, Gary K; Keohan, Mary Louise et al. (2016) Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial. JAMA Oncol 2:937-40

Showing the most recent 10 out of 336 publications